Skip to main content
logo
AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.8200
-0.0600 (-6.82%)
At close: May 13, 2026, 4:00 PM EDT
0.8017
-0.0183 (-2.23%)
After-hours: May 13, 2026, 8:00 PM EDT

Company Description

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.

It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.

It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

AEON Biopharma, Inc.
AEON Biopharma logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees8
CEORobert Bancroft

Contact Details

Address:
5 Park Plaza, Suite 1750
Irvine, California 92614
United States
Phone949 354 6499
Websiteaeonbiopharma.com

Stock Details

Ticker SymbolAEON
ExchangeNYSEAMERICAN
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code1837607
CUSIP Number00791X209
ISIN NumberUS00791X2099
Employer ID85-3940478
SIC Code2834

Key Executives

NamePosition
John A. Bencich M.B.A.Chief Financial Officer
Jennifer SyChief Accounting Officer

Latest SEC Filings

DateTypeTitle
Apr 29, 2026ARSFiling
Apr 29, 2026DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2026DEF 14AOther definitive proxy statements
Apr 3, 20268-KCurrent Report
Mar 31, 2026S-8Securities to be offered to employees in employee benefit plans
Mar 30, 202610-KAnnual Report
Mar 30, 20268-KCurrent Report
Mar 9, 20268-KCurrent Report
Feb 18, 2026424B3Prospectus
Feb 17, 2026EFFECTNotice of Effectiveness
View All SEC Filings